NCT06193486View on ClinicalTrials.gov

Autologous Gamma Delta T Cells to Target Prostate Stem Cell Antigen in mCRPC

PHASE1RecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

October 26, 2024

Primary Completion Date

January 13, 2029

Study Completion Date

December 13, 2033

Conditions
Metastatic Castration-resistant Prostate Cancer
Interventions
BIOLOGICAL

MSGV1-PSCA-8T28Z

Autologous Gamma Delta T Cells Genetically Engineered with a Chimeric Receptor to Target the Prostate Stem Cell Antigen.

DRUG

Fludarabine

Fludarabine is an antimetabolite given prior to lymphodepletion.

DRUG

Cyclophosphamide

Cyclophosphamide is a nitrogen mustard-derivative, polyfunctional alkylating agent given prior to lymphodepletion.

Trial Locations (1)

33612

RECRUITING

Moffitt Cancer Center, Tampa

All Listed Sponsors
lead

H. Lee Moffitt Cancer Center and Research Institute

OTHER